17 November 2026 | Tuesday | News
Image Source: Public Domain
Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria. Gazyva/Gazyvaro becomes the first and only therapy to receive FDA approval for this disease, having previously been granted Breakthrough Therapy Designation. A chronic autoimmune disease that can lead to kidney failure, pMN carries a substantial human and economic burden for patients, caregivers and health systems alike.1,2 Proteinuria is a key indicator of kidney damage characterised by high urine protein levels.
“The FDA approval of Gazyva/Gazyvaro represents an important step forward for people living with primary membranous nephropathy, where targeting B cells addresses a critical underlying driver of disease,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “With Gazyva/Gazyvaro, we are turning decades of specialised antibody engineering into tangible outcomes for patients with immune-mediated kidney diseases. By achieving significantly higher complete remission rates compared to tacrolimus, Gazyva/Gazyvaro offers a more effective approach to help achieve durable
disease control.”
The approval is based on positive results from the phase III MAJESTY study.3 The trial met its primary endpoint, with 36.1% of adults achieving complete remission (CR) of proteinuria at two years (104 weeks) with Gazyva/Gazyvaro versus 5.7% with tacrolimus (adjusted difference 31.1%; 95% confidence interval [CI]: 18.2 to 44.0; p<0.001). Key secondary endpoints showed that Gazyva/Gazyvaro was superior to tacrolimus in achieving overall remission (complete or partial remission) at week 104 (50% vs. 12.9%; adjusted difference 37.8%; 95% CI: 23.9 to 51.8; p<0.001) and complete remission at week 76 (36.1% vs. 8.6%; adjusted difference 27.4%; 95% CI: 13.4 to 39.8; p<0.001). Safety was in line with the well-characterised profile of Gazyva/Gazyvaro and no new safety signals were identified. MAJESTY data were featured at the 63rd European Renal Association (ERA) Congress in June 2026 as a late-breaking oral presentation and published in the New England Journal of Medicine (NEJM). Data are also being submitted to other global health authorities, including the European Medicines Agency.
“People living with primary membranous nephropathy face the risk of progressive kidney damage and significant uncertainty about their health,” said Marc Hurlbert, PhD, Chief Executive Officer of the National Kidney Foundation. “The first FDA approval of a treatment specifically for this condition is a milestone, finally giving patients and clinicians more treatment options. Our hope is that the approval of Gazyva/Gazyvaro provides a turning point for people navigating pMN.”
pMN is a rare, chronic autoimmune condition that causes potentially irreversible kidney damage and can lead to kidney failure. People living with pMN often experience fatigue, edema (swelling) and significant emotional and social challenges that deeply affect both patients and their families.1,4 Beyond the individual impact, pMN places a substantial burden on healthcare systems.2,5 Achieving complete remission is important to help maintain kidney function and delay or prevent the onset of serious and potentially fatal complications.2
“pMN can lead to debilitating physical and psychological symptoms that place a heavy burden on patients, families and healthcare systems alike,” said Teresa Graham, Chief Executive Officer, Roche Pharmaceuticals. “This first-ever FDA approval delivers an important targeted treatment option for the pMN community and expands how many people may benefit from Gazyva/Gazyvaro across multiple severe immune-mediated kidney diseases.”
This is the third FDA approval of Gazyva/Gazyvaro in immune-mediated kidney diseases, following approvals in idiopathic nephrotic syndrome (INS) and lupus nephritis (LN). The FDA is currently evaluating Gazyva/Gazyvaro for adults with systemic lupus erythematosus (SLE) and is expected to make a decision by December 2026. Additionally, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recently issued a positive opinion recommending the approval of Gazyva/Gazyvaro for adults with SLE, with a final decision from the European Commission expected in the near future. Beyond Gazyva/Gazyvaro, Roche has a broad pipeline to bring breakthrough innovation across immunology, including immune-mediated kidney diseases.
© 2026 Biopharma Boardroom. All Rights Reserved.